New Path is delighted to have been selected an oncology accelerator programme funded by Cancer Research Horizons and Innovate UK. The selection process was highly competative with just eight companies selected from over one hundred applications. The accelerator will assist in the development of New Path’s tumour agnostic drug conjugate programme through expert advice, pharma interaction and entrepreneurship and innovation training from professors at the UC Berkley UC Haas School of Business
New Path is Selected for Cancer Research Horizons & Innovate UK Oncology Accelerator